The historical rank and industry rank for Sorrento Therapeutics's Net Margin % or its related term are showing as below:
SRNE'
s Net Margin % Range Over the Past 10 Years
Min: -4763.26 Med: -908.84 Max: 6.01
Current: -852.8
SRNE's Net Margin % is ranked worse than 71.08% of 1027
companies
in the Biotechnology industry
Industry Median: -160.92
vs SRNE: -852.80
Sorrento Therapeutics Net Margin % Historical Data
The historical data trend for Sorrento Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sorrento Therapeutics's Net Margin %
For the Biotechnology subindustry, Sorrento Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sorrento Therapeutics's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sorrento Therapeutics's Net Margin % falls into.
Sorrento Therapeutics Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Sorrento Therapeutics's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sorrento Therapeutics (OTCPK:SRNE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sorrento Therapeutics Net Margin % Related Terms
Thank you for viewing the detailed overview of Sorrento Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sorrento Therapeutics (Sorrento Therapeutics) Business Description
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRNE has been successfully added to your 